» Articles » PMID: 6581385

Cornstarch Therapy in Type I Glycogen-storage Disease

Overview
Journal N Engl J Med
Specialty General Medicine
Date 1984 Jan 19
PMID 6581385
Citations 86
Authors
Affiliations
Soon will be listed here.
Citing Articles

Safety and Efficacy of DTX401, an AAV8-Mediated Liver-Directed Gene Therapy, in Adults With Glycogen Storage Disease Type I a (GSDIa).

Weinstein D, Derks T, Rodriguez-Buritica D, Ahmad A, Couce M, Mitchell J J Inherit Metab Dis. 2025; 48(2):e70014.

PMID: 40064185 PMC: 11893205. DOI: 10.1002/jimd.70014.


Base-editing corrects metabolic abnormalities in a humanized mouse model for glycogen storage disease type-Ia.

Arnaoutova I, Aratyn-Schaus Y, Zhang L, Packer M, Chen H, Lee C Nat Commun. 2024; 15(1):9729.

PMID: 39523369 PMC: 11551175. DOI: 10.1038/s41467-024-54108-1.


Gene therapy and genome editing for type I glycogen storage diseases.

Chou J, Mansfield B Front Mol Med. 2024; 3:1167091.

PMID: 39086673 PMC: 11285695. DOI: 10.3389/fmmed.2023.1167091.


Short and long-term acceptability and efficacy of extended-release cornstarch in the hepatic glycogen storage diseases: results from the Glyde study.

Weinstein D, Jackson R, Brennan E, Williams M, Davison J, de Boer F Orphanet J Rare Dis. 2024; 19(1):258.

PMID: 38982397 PMC: 11232220. DOI: 10.1186/s13023-024-03274-y.


Inhibition of Wnt/β-catenin signaling reduces renal fibrosis in murine glycogen storage disease type Ia.

Lee C, Pratap K, Zhang L, Chen H, Gautam S, Arnaoutova I Biochim Biophys Acta Mol Basis Dis. 2023; 1870(1):166874.

PMID: 37666439 PMC: 10841171. DOI: 10.1016/j.bbadis.2023.166874.